Which drug class does tucatinib belong to?

Tucatinib belongs to the drug class of tyrosine kinase inhibitors (Tyrosine Kinase Inhibitor, referred to as TKI). Tyrosine kinase inhibitors are a class of drugs that inhibit the activity of tyrosine kinases. Tyrosine kinases are key enzymes in intracellular signaling pathways. They play an important role in regulating cell proliferation, differentiation, apoptosis and other physiological processes. When tyrosine kinase is abnormally activated, it promotes the proliferation and spread of cancer cells, leading to the occurrence and development of tumors. TKIBy specifically binding to the active site of tyrosine kinase, inhibiting its catalytic activity, thereby blocking the signal transduction pathway of cancer cells, achieving the purpose of inhibiting tumor growth and spread.

Tucatinib is a highly selective TKI that primarily inhibits HER2 (human epidermal growth factor receptor 2), a specific type of tyrosine kinase. This high selectivity allows tucatinib to act more precisely on HER2-positive cancer cells while reducing damage to normal cells.

Tucatinib is an oral small molecule drug that can be administered to patients conveniently orally without the need for intravenous injection or other invasive administration methods, which greatly improves the convenience and comfort of patients.

Compared with some otherTKIs, tucatinib has the ability to penetrate the blood-brain barrier. This gives it a unique advantage in treating brain metastases, as many other anticancer drugs are ineffective in treating brain metastases due to their inability to penetrate the blood-brain barrier.

Tucatinib is mainly used to treat HER2 positive breast cancer and colorectal cancer and other malignant tumors. In clinical practice, it is often used in combination with other HER2-targeted drugs (such as trastuzumab) to improve the therapeutic effect. By inhibiting the activity of HER2, tucatinib can block the signaling pathways of cancer cells, thereby inhibiting the growth and spread of tumors and bringing survival benefits to patients.

References:

https://www.drugs.com/tucatinib.html